Crystalline Salt Forms of PPARδ Agonists for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable and effective crystalline salt forms of PPARδ agonists, such as Compound A and Compound B, that can be easily manufactured and delivered as pharmaceutical formulations to treat PPARδ-related diseases, which require specific physical properties and stability for large-scale production and therapeutic efficacy.
Innovation Solution
The development of hemisulfate and meglumine salt forms of Compound A and Compound B, respectively, which are characterized by specific X-ray powder diffraction patterns and are stable, allowing for effective crystallization and pharmaceutical compositions that can be administered to treat PPARδ-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline salt forms of PPARδ agonists are developed for pharmaceutical use, then stability and bioavailability are enhanced, but manufacturing complexity increases due to the need for specific crystallization processes and characterization
Solution Approach 1:
The patent applies parameter changes by systematically varying salt formers (different counterions), solvents, and crystallization conditions to obtain distinct crystalline polymorphs of PPARδ agonists. Each polymorph has specific physical parameters (melting point, solubility, stability) that are optimized for pharmaceutical use while maintaining manufacturability through controlled crystallization processes.
Solution Approach 2:
The patent utilizes phase transitions by inducing crystallization from solution or melt to form stable solid-state polymorphs. The controlled phase transition from amorphous or solvated states to defined crystalline structures enhances stability and bioavailability while providing reproducible manufacturing pathways through standardized crystallization protocols.
2Reliability
If multiple salt forms and polymorphs are developed to optimize therapeutic efficacy, then treatment effectiveness improves, but the number of formulations and manufacturing processes increases
Solution Approach 1:
The patent segments the development into distinct salt forms and polymorphs, each with optimized properties for specific therapeutic indications. By dividing the formulation space into discrete, characterized entities (e.g., hemisulfate monohydrate, meglumine polymorphs), the patent enables selective manufacturing of only the most effective forms for each indication, improving overall productivity.
Solution Approach 2:
The patent establishes universal crystallization methodologies and characterization protocols that can be applied across multiple salt forms and polymorphs. The standardized approaches to synthesis, purification, and analysis enable efficient scaling from laboratory to manufacturing while maintaining consistency across different formulations.
3Ease of manufacture
If amorphous or solvated forms are used for easier manufacturing, then production simplicity increases, but stability and shelf-life decrease
Solution Approach 1:
The patent employs solvents and salt formers as intermediaries that facilitate easy manufacturing during processing, then are removed or converted to stable crystalline forms for final product. The crystallization process acts as an intermediary step that transforms easily manufactured solvated intermediates into stable, shelf-ready crystalline pharmaceuticals.
Solution Approach 2:
The patent performs preliminary crystallization and stabilization steps during manufacturing to lock the compound into stable polymorphic forms before packaging and storage. By establishing the stable crystalline structure early in the process, subsequent handling and storage become simpler while maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline salt forms of Compound A and Compound B provide enhanced stability and bioavailability, enabling effective treatment of PPARδ-related diseases by modulating PPARδ activity, thus addressing the challenges of stability and delivery in existing formulations.
Implementation Method 1
the crystalline the hemisulfate salt of Compound A is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 1 or FIG. 2
Data Source
AI summary
This disclosure relates to salt forms of compounds capable of activating PPARδ for use in drug substance and drug product development, and related compositions and methods.